What the FDA labels say about taking them together
Agalsidase beta and epinephrine
Agalsidase beta's FDA label of August 22, 2025 names epinephrine in its boxed warning section; the epinephrine labels PlainMeds reads (4) do not name agalsidase beta.
Check it at the source: the agalsidase beta FDA label on DailyMed (effective August 22, 2025, Genzyme Corporation); the epinephrine FDA label on DailyMed (effective July 13, 2026, A-S Medication Solutions).
What does the agalsidase beta label say about epinephrine?
Agalsidase beta label, boxed warningIf a severe hypersensitivity reaction (e.g., anaphylaxis) occurs, discontinue FABRAZYME and immediately initiate appropriate medical treatment, including use of epinephrine.
Source: FDA drug label (Fabrazyme), Genzyme Corporation, effective August 22, 2025 (SPL set 988513ab-b06f-4dd0-93f7-d2d4531dcce4), via openFDA; the full label on DailyMed
What does the epinephrine label say about agalsidase beta?
Epinephrine's label (effective July 13, 2026) and its 3 other brand-application labels do not name agalsidase beta in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Epinephrine), A-S Medication Solutions, effective July 13, 2026 (SPL set 6e811e28-0199-4df7-a916-5940c632401d), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Agalsidase beta | Epinephrine | |
|---|---|---|
| Labeled for | n/a | Asthma |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $123.51 per unit 0.15 mg auto-injct |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once